What's Next for New York Cannabis

$2.5 billion projected by 2027, federal rescheduling on the horizon, and the challenges that remain. The future of cannabis in the Empire State.

Last verified: March 2026

Market Trajectory

The legal market's trajectory points sharply upward. Industry analysts project $2.5 billion+ in sales by 2027, with the dispensary count continuing to grow from 582 toward potentially 750+ by year-end 2026. Monthly sales reached $168 million in January 2026, up from $34 million in February 2024.

Average prices are compressing — down 12.7% year-over-year — though New York still has the highest average prices among major US markets at $31.49 per item.

Federal Rescheduling

President Trump signed an executive order in December 2025 directing the DEA to expedite moving cannabis from Schedule I to Schedule III. If completed, the most immediate impact would be elimination of the 280E tax burden that prevents cannabis businesses from deducting ordinary expenses like rent and payroll. This could dramatically improve profitability for legal operators struggling against untaxed competitors.

However, rescheduling would not:

  • Legalize recreational cannabis federally
  • Enable interstate commerce
  • Resolve banking challenges without further action

Key Developments to Watch in 2026

  • School proximity fix — OCM's reinterpretation of distance rules threatened 152 dispensaries in mid-2025, most of them minority-owned. A legislative fix is expected.
  • Chief equity officer role — Potential restoration to its original oversight capacity
  • Enforcement posture — New Mayor Zohran Mamdani has not yet signaled his approach to the unlicensed market
  • Metrc stabilization — The seed-to-sale tracking system launched December 2025 needs time to mature
  • Supply chain growth — Projected 2025 in-state yield covers only about 50% of anticipated 2026 demand

The Fundamental Challenge

The fundamental math has not changed: legal cannabis taxed at 20%+ and burdened with compliance costs will struggle to compete on price until the illicit market is materially reduced. The state's prohibition on vertical integration protects small operators but complicates supply chain efficiency.

The Big Picture

New York's cannabis story defies simple narrative. It is simultaneously the nation's most ambitious equity experiment and its most dysfunctional regulatory rollout. It hosts both America's fastest-growing legal market and its most entrenched illicit one. What has emerged is something no other state has produced: a cannabis market that is messy, culturally electric, deeply flawed, and genuinely transformative — all at once.